Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
BRIEF: CSPC Pharma profit dips on falling drug revenue
CSPC Pharmaceutical Group Ltd. (1093.HK) warned on Thursday that is net profit for the first nine months of this year fell about 16% compared with a year earlier. It blamed the…
FAST NEWS: CSPC Pharma’s urticaria drug approved in China
The Latest: CSPC Pharmaceutical Group Ltd. (1093.HK) announced on Tuesday that its chronic spontaneous urticaria treatment, Omalizumab for Injection, has been approved for sale in China by the country’s National Medical Products Administration…
CSPC Pharma taps R&D superstar in quest for new breakout drugs
Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
The pharmaceutical company posted an 11% rise in half-year revenue, helped by growing income from innovative medicines, as it pivots away from the generic drug business Key Takeaways: Revenue from…
CSPC Pharma weighs up diet drug for bigger bottom line
After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business Key Takeaways: CSPC…
Profit setback for Simcere Pharma in novel drugs quest
The pharmaceutical company’s profits have been buffeted by erratic returns on an equity stake in a fellow developer of innovative drugs Key Takeaways: Simcere Pharmaceutical holds a 9% stake in…